Featured
Bank CF+ Gets Permission to Operate in Germany and Partners with Raisin for Deposit Accounts
Bank CF+ is the challenger bank created after the spinoff from the former Credito Fondiario a year ago of the management and investment activities in impaired loans transferred to Gardant Group. Banca CF+, as well as the spun-off Gardant, is 88 percent controlled by the U.S. fund Elliott through Tiber Investments sarl,
Banca CF+ has obtained authorization to conduct banking business in Germany under the freedom to provide services and has signed a partnership with the fintech company Raisin to make its deposit accounts available to German savers through the Weltsparen and Zinspilot platforms of the same Raisin, which already announced a similar partnership with IBL Banca in early July and which in May 2019 had signed such a partnership with illimity bank.
Read more about Bank CF+ and find the latest business headlines of the day with the Born2Invest mobile app.
Banca CF+ is the challenger bank created after the spinoff from the former Credito Fondiario
For all aspects of the authorization process in Germany, as well as the structuring and negotiation of the legal and regulatory profiles of the transaction, Banca CF+ was assisted by Bird & Bird.
To date, Raisin offers its customers in Europe and the United States access to overnight and term interest-bearing deposits at more than 160 international partner banks and manages a savings volume of more than $25.4 billion (€25 billion). In December 2020, the German fintech company signed a partnership with Banca Sella to enable its customers to access deposit accounts at other banks, both Italian and European, by transferring money from their current account to their chosen deposit account and keeping it monitored until the maturity of the bond.
Founded in 2012 by Frank Freund, Michael Stephan, and Tamaz Georgadze, Raisin has since raised a total of about $240 million from venture capital investors, with the latest round going back to last January when Goldman Sachs (already an investor in the scaleup) and Hedosophia subscribed for $30.4 million (€30 million) in convertible bonds. Meanwhile, the company has already mandated Goldman Sachs to seek investors for a new round. Country manager Italy is Federico Roesler Franz.
Led by Iacopo De Francisco, managing director and general manager, who was already a guest before Easter on BeBeez Live, Banca CF+ is the challenger bank created after the spinoff from the former Credito Fondiario a year ago of the management and investment activities in impaired loans transferred to Gardant Group. Banca CF+, as well as the spun-off Gardant, is 88 percent controlled by the U.S. fund Elliott through Tiber Investments sarl, with the rest of the capital held by the shareholders of Tages (12 percent), an investment company founded in 2011 by investment bankers Panfilo Tarantelli and Sergio Ascolani, and present in the bank’s capital since 2013.
The 5-year business plan aims to reach $4.26 billion (€4.2 billion) in assets under management and to achieve efficiency and profitability targets that are among the highest in the banking system, summarized as a cost/income ratio of 42 percent and a Roae (return on average equity) of 23 percent. All this with a net profit of 50 million and 200 employees from the current 100. To achieve the goals of the plan, Bank CF+ is targeting SMEs with turnover between $2.03 and $101.4 million (€2 and €100 million): more than 200 thousand companies, with 5.5 million employees, that have low ratings and received little credit from banks between 2010 and 2019. To these companies, the bank will offer, using an evolved technological platform, several specialized financing solutions for the business: factoring (without and with recourse), financing guaranteed or not guaranteed by MCC and SACE, purchase of tax credits
__
(Featured image by Tama66 via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Be Beez, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
-
Biotech6 days ago
Novo Nordisk: Ozempic Gets Positive Evaluation for Kidney Treatment
-
Impact Investing2 weeks ago
Hera Receives 10 Million Euros from the PNRR for Agrivoltaics
-
Crypto3 days ago
Blackrock Just Launched the RWA Tokenization Snowball. Here’s How to Profit With SurancePlus [NASDAQ: OXBR]
-
Cannabis1 week ago
Coffee Shops in Only 10 Dutch Cities Will Sell Legal Cannabis from April 2025